“Sweat equity takes on a whole new meaning when you’re networking in a hot room,” says Chad Messer, a managing director at US ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, varegacestat for desmoid tumors, is not an ...

Enthusiasts say high-temperature sessions sharpen focus, improve health, and offer a chance to build contacts. It’s a far cry ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab IMAB offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...